Table 1.

CRISPR-SeroSeq summary results of Salmonella-positive samples from GPLN (n = 568).

Serovara	Frequencyb	Present (%)c	Alone (%)d	Major (%)e	Average relative frequency (%)f	Monthsg	Companiesh
Kentucky I	462	81.3	86	65	94	23	20
Cerro	43	7.6	30	57	65	10	5
Mbandaka	34	6	12	17	30	15	7
Typhimurium	25	4.4	32	41	62	14	11
Liverpool	21	3.7	29	53	58	11	6
Infantis	19	3.3	16	12	38	11	6
Alachua	17	3	47	11	61	6	2
Senftenberg II	12	2.1	8	18	36	8	6
Tennessee	9	1.6	11	25	36	5	5
Enteritidis	8	1.4	62	0	72	5	7
Uganda	8	1.4	12	57	49	5	1
Montevideo I	6	1.1	0	17	18	4	3
Montevideo II	6	1.1	0	0	4	3	4
Agona	5	0.9	40	0	45	3	3
Altona	5	0.9	20	25	39	5	2
Anatum	5	0.9	20	25	42	2	3
Untypeable	5	0.9	20	0	32	3	2

^aOnly serovars present in five or more samples were included (n = 17), including five serovars of clinical importance (bolded), that are most often causing outbreaks (Center for Disease Control and Prevention BEAM Dashboard). The suffixes (-I, -II, -III) for some serovars refer to polyphyletic lineages.

^bIndicates the total number of samples each serovar was found in.

^cIndicates the total percentage of samples each serovar was found in.

^dIndicates how often a serovar was the single serovar in a sample.

^eIndicates the frequency in which the serovar was present at a higher relative frequency in a mixed population of multiple serovars.

^fThis was calculated across all “present” samples.

^gIndicates how many months (n = 24) each serovar was identified in.

^hIndicates how many companies (n = 22) each serovar was identified from.